SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is experiencing significant volatility driven by reports of engineering setbacks affecting the launch of its anticipated foldable iPhone, alongside ongoing legal pressures from a patent infringement dispute. While some market participants are reacting with caution to these headwinds, the community remains actively divided, with many bulls dismissing the news as temporary noise and focusing on the company's long-term ecosystem stability.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axon Enterprise is experiencing significant downward pressure as investors rotate out of high-multiple software stocks, leading the community to intensely debate whether the current slide represents a fundamental repricing or a major buying opportunity. Despite recent announcements of new AI-driven product tools, the stock continues to face sharp volatility and sentiment shifts as stakeholders express frustration over the ongoing sell-off while waiting for upcoming earnings and industry events to provide a clear path forward.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is currently attracting significant attention following the announcement of a landmark long-term partnership with Google to co-develop custom AI chips through 2031. The community is actively discussing this as a pivotal move that cements the company's role as essential infrastructure for AI hyperscalers, with many investors debating whether this solidifies a bullish long-term outlook despite recent macro-driven volatility.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors remain focused on its high short interest and potential for a squeeze, with ongoing community debate regarding the company's lack of major acquisitions and frustration over stagnant price action. Market participants are actively comparing GME's current activity to historical trading patterns, closely monitoring volume, and analyzing the impact of off-exchange routing on price discovery.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz Global Holdings Inc

Hertz is seeing heightened volatility and active options sentiment as traders debate its potential for a short squeeze, particularly as the stock's performance is often compared to sector peer Avis. Investors are closely monitoring price action around the $6 level while keeping a watchful eye on high short interest, institutional positioning, and the broader macro environment for travel demand.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing significant volatility driven by a high short interest and aggressive retail trading, fueling intense speculation about a potential short squeeze. Investors remain polarized, with community discussion split between those capitalizing on the parabolic price action and others warning that the company's underlying fundamentals are weak.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is surging following a better-than-expected CMS announcement that finalized a 2.48% payment increase for 2027 Medicare Advantage plans, significantly alleviating recent regulatory concerns. Investors and the community are interpreting this as a major relief catalyst, sparking discussions about a potential short squeeze and a long-term recovery trajectory for the insurance sector.

Kimberly-Clark Corp. engages in the manufacture and marketing of products made from natural or synthetic fibers. It operates through North America and International Personal Care segments. The North America segment consists of products encompassing each of daily-need categories across consumer and professional channels including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers and other related products. The International Personal Care segment consists of three core categories: Baby & Child Care, Adult Care, and Feminine Care, including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear and other related products. The company was founded by John A. Kimberly, Havilah Babcock, Charles B. Clark, and Frank C. Shattuck in 1872 and is headquartered in Dallas, TX.

Kimberly-Clark Corp.

Kimberly-Clark is facing intense downward pressure and high volatility following the announcement of its massive acquisition of Kenvue. While some investors are aggressively accumulating shares to lock in a dividend yield that has risen significantly with the price drop, the broader community remains divided, with many debating the long-term impact of the acquisition's debt load, potential dilution, and the legal uncertainties surrounding Tylenol litigation.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The S&P 500 is experiencing heightened volatility as market participants react to geopolitical tensions in the Middle East, specifically revolving around a deadline for a potential ceasefire deal with Iran. Investors are actively debating whether the market's resilience signals a buy the dip opportunity or a dangerous bull trap fueled by algorithmic trading and aggressive news cycle headlines.

Leishen Energy Holding Co., Ltd. is engaged in the oil and gas industry. It operates through the following business segments; Clean-Energy Equipment; Oil and Gas Engineering Technical Services; New Energy Production and Operation; and Digitalization and Integration Equipment. The Clean-Energy Equipment segment supplies wellhead heating systems, wellhead safety control systems, oil-water separation systems, natural gas online sampling systems, oil and gas skid-mounted equipment and polymer flexible composite pipes. The Oil and Gas Engineering Technical Services segment provides technical solutions for oil and gas production. The New Energy Production and Operation segment focuses on the production, storage and transportation of natural gas, traditional fuels, development of distributed energy, and the planning and operation of new energy and new energy industries. The Digitalization and Integration Equipment segment is designed to provide informatization solutions for industrial intelligence, mobility, industrial interconnection and big data trends. The company was founded by Hongqi Li in 2007 and is headquartered in Beijing, China.

Leishen Energy Holding Co Ltd - Ordinary Shares - Class A

Leishen Energy Holding Co Ltd

Leishen Energy (LSE) is seeing significant retail interest and volatility driven by its profile as a low-float, energy-sector play that some traders are comparing to previous explosive small-cap runners. While some investors are optimistic about its potential for momentum and future growth in the Middle East, others in the community are actively warning of potential pump-and-dump mechanics, citing the lack of significant news to justify the recent price swings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MacroGenics (NASDAQ:MGNX) Share Price Crosses Above Fifty Day Moving Average   - Time to Sell?

MacroGenics (NASDAQ:MGNX) Shares Pass Above 50-Day Moving Average - Time to Sell...

MacroGenics (NASDAQ:MGNX) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen raised MacroGenics from a "sell" rating to a "hold" rating in a report on Saturday...

<ul class="summary-bullets"><li>Barclays sees the company's antibody-drug conjugate data in 2026 as a potential source of upside.</li><li>MacroGenics CEO Eric Risser said on Monday that the company anticipates several important milestones in 2026, including initial clinical data from the early-stage studies of antibody drug conjugates MGC026 and MGC028.&nbsp;</li><li>The company also seeks to submit an application seeking clearance to start clinical trials for its other ADC MGC030 in the third quarter of 2026.</li></ul> Barclays on Tuesday raised the firm's price target on MacroGenics on optimism regarding its pipeline of targeted cancer therapies.Barclays increased the price target on MacroGenics (MGNX) to $4 from $3 and kept an ‘Overweight’ rating on the shares following the company’s Q4 report on Monday. The firm sees the company's antibody-drug conjugate data in 2026 as a potential source of upside.<h2 class="st-heading-2">Pipeline Updates</h2>MacroGenics CEO Eric Risser said on Monday that the company anticipates several important milestones in 2026, including initial clinical data from the early-stage studies of antibody drug conjugates MGC026 and MGC028, and from a study of its other experimental drug lorigerlimab.The company also seeks to submit an application seeking clearance to start clinical trials for its other ADC MGC030 in the third quarter of 2026, Risser said.Antibody-drug conjugates (ADCs) are targeted cancer therapies that deliver chemotherapy directly to cancer cells, minimizing damage to healthy tissue. Both Macrogenics’ MGC026 and MGC028 have demonstrated acceptable safety profiles to date as well as encouraging early evidence of anti-tumor activity. The company now anticipates reporting MGC026 clinical data in mid-2026, and MGC028 clinical data in the second half of 2026.Meanwhile, the U.S. Food and Drug Administration has placed a partial clinical hold on the company’s study evaluating lorigerlimab in patients with either platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). The company said that it is working closely with the agency to resolve the hold “as soon as possible” and anticipates a clinical update in mid-2026.The company ended the year with cash, cash equivalents and marketable securities of $189.9 million, which it expects to support its cash runway into late 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MGNX stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/MGNX">MGNX stock</a> has gained more than 50% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/viking-ceo-sees-its-obesity-drug-beating-novo-wegovy-in-weight-loss/cZdozzNRI7l">Viking CEO Sees Its Obesity Drug Beating Novo's Wegovy In Weight Loss</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

MGNX Closes Up 45% On Wall Street Optimism For Experimental Cancer Therapies

Barclays increased the price target on the stock to $4 from $3 and kept an ‘Overweight’ rating on the shares. 

Equity

Barclays increased the price target on the stock to $4 from $3 and kept an ‘Overweight’ rating on the shares. 


Barclays Forecasts Strong Price Appreciation for MacroGenics (NASDAQ:MGNX) Stock

Barclays increased their price target on MacroGenics from $3.00 to $4.00 and gave the company an "overweight" rating in a research report on Tuesday...

MacroGenics (NASDAQ:MGNX) Announces Quarterly Earnings Results, Beats Estimates By $0.20 EPS

MacroGenics (NASDAQ:MGNX - Get Free Report) announced its earnings results on Monday. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of...

MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of +47.31% and +71.24%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BioLife Solutions, Inc. (BLFS) Surpasses Q4 Earnings and Revenue Estimates

BioLife Solutions (BLFS) delivered earnings and revenue surprises of +300.00% and +5.16%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Recommendation of "Hold" from Analysts

MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) has been given a consensus rating of "Hold" by the seven ratings firms that are covering the firm, Marketbeat reports. One investment analyst has...

MacroGenics (NASDAQ:MGNX) Stock Crosses Below 200-Day Moving Average - Should You Sell?

MacroGenics (NASDAQ:MGNX) Shares Pass Below 200 Day Moving Average - Here's What Happened...

MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by Analysts

Shares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have received an average recommendation of "Hold" from the seven ratings firms that are covering the firm, MarketBeat reports. One equities...

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

MGNX
Macrogenics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MGNX News

MGNXMacrogenics Inc